Alzheimer’s disease therapies in phase III development 2024, by type

Alzheimer’s disease drugs in clinical trial phase III worldwide as of 2024, by type

CharacteristicShare of drugs in phase III
Neurotransmitter receptor 34%
Amyloid 22%
Synaptic plasticidy/neuroprotection 12%
Proteostasis/proteinopathies 6%
Inflammation 6%
Metabolism/bioenergetics 6%
Other 14%
Created with Highcharts 7.2.2Share of drugs in phase III34%34%22%22%12%12%6%6%6%6%6%6%14%14%Neurotransmitter receptorAmyloidSynaptic plasticidy/neuroprotectionProteostasis/proteinopathiesInflammationMetabolism/bioenergeticsOther
0%10%20%30%2.5%5%7.5%12.5%15%17.5%22.5%25%27.5%32.5%35%37.5%
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

April 2024

Region

Worldwide

Survey time period

as of January 1, 2024

Supplementary notes

There were 32 Alzheimer's disease drugs in phase III as of January 1, 2024.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Leading companies trust Statista:
paypal google adobe pg samsung telekom
Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on " Dementia and Alzheimer's disease in Europe "

Other statistics that may interest you Dementia and Alzheimer's disease in Europe

World overview

6

European focus

5

Mortality and morbidity

8

Situation in specific countries

8

Policies directed towards dementia

8

Further related statistics

10

Discover Statista

Need help with using Statista for your research? Tutorials and first steps
Do you have any questions about our business solutions?

We provide you with detailed information about our Professional Account.

Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Learn more about how Statista can support your business.